Previous close | 3.9400 |
Open | 3.9900 |
Bid | 3.7300 x 100 |
Ask | 3.8100 x 100 |
Day's range | 3.7300 - 3.9900 |
52-week range | 1.4200 - 11.9700 |
Volume | |
Avg. volume | 575,187 |
Market cap | 223.993M |
Beta (5Y monthly) | 1.44 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.5100 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 9.25 |
LEXINGTON, Mass., May 08, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced enrollment of the first patient in a Phase 3 dry eye chamber clinical trial designed to enable a potential resubmission of the New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye dise
LEXINGTON, Mass., April 25, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.